Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Recombinant Human Adenovirus Type 5 (H101) in Advanced Hepatocellular Carcinoma Patients With Stable Disease After Sorafenib Treatment: A Randomized, Parallel-Controlled Clinical Trial

NCT05113290 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT05113290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Recombinant Human Adenovirus Type 5 (H101) in Advanced Hepatocellular Carcinoma Patients With Stable Disease After Sorafenib Treatment: A Randomized, Parallel-Controlled Clinical Trial
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 4
Overall status
Unknown status
Start date
December 28, 2021
Completion date
December 1, 2023
Enrollment
66 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma